Lanreotide Acetate Injection
Product Images NDC 76282-718

Product Visual Gallery

This gallery contains 36 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 76282-718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lanreotide Structure (Lanreotide Structure)

Chemical structure diagram of lanreotide acetate showing the peptide sequence with specific amino acid residues and disulfide bonds, as well as the acetate group with variable substitution (x = 1.0 to 2.0).*

FDA Label Image

Lanreotide Fig 1 (Lanreotide Fig 1)

A Kaplan-Meier survival curve chart showing progression-free survival probability (%) over time in months for Lanreotide Injection versus Placebo groups. The chart includes censored survival data with risk table counts below the x-axis, illustrating higher survival probability in the Lanreotide group across up to 24 months.*

FDA Label Image

Lanreotide Fig 2 (Lanreotide Fig 2)

Illustrative diagram showing a packaged vial of LANREOTIDE ACETATE injection stored inside a refrigerator next to a carton labeled 'MILK.' The diagram highlights proper refrigerated storage conditions for the medication.*

FDA Label Image

Lanreotide Fig 3 (Lanreotide Fig 3)

Two-panel illustration related to LANREOTIDE ACETATE injection. The top panel features a calendar displaying August 28, likely indicating a date to remember. The bottom panel depicts a rectangular box, presumably a packaging container for the medication, viewed partially open to reveal its contents inside.*

FDA Label Image

Lanreotide Fig 4 (Lanreotide Fig 4)

An instructional illustration showing an hourglass next to an opened package with an injection device, indicating a wait time of 30 minutes, likely for the LANREOTIDE ACETATE injection before administration.*

FDA Label Image

Lanreotide Fig 5 (Lanreotide Fig 5)

An instructional diagram showing appropriate subcutaneous injection sites for LANREOTIDE ACETATE. The first image depicts a standing person with approved injection areas on the right and left buttocks. The second image shows a person lying down with a designated acceptable injection site on the upper buttock. Both diagrams are labeled with 'OK' at the injection sites.*

FDA Label Image

Lanreotide Fig 6 (Lanreotide Fig 6)

An instructional illustration showing a hand holding several small spherical objects under a running water faucet, likely demonstrating rinsing or cleaning technique.*

FDA Label Image

Lanreotide Fig 7 (Lanreotide Fig 7)

An instructional illustration depicting a hand opening a sealed packet or pouch, likely part of medication preparation or administration steps for LANREOTIDE ACETATE injection.*

FDA Label Image

Lanreotide Fig 8 (Lanreotide Fig 8)

An illustration diagram showing a pre-filled syringe for injection. The syringe components labeled include the tray, needle cap, pre-filled syringe body, and expiration date and dose label. The syringe is contained within a molded tray for safe handling.*

FDA Label Image

Lanreotide Fig 9 (Lanreotide Fig 9)

An instructional illustration depicting a pre-filled syringe labeled for lanreotide acetate injection. The label area includes placeholders for strength, expiration date, and lot number. The syringe is designed for subcutaneous administration, featuring a plunger handle and needle cover.*

FDA Label Image

Lanreotide Fig 10 (Lanreotide Fig 10)

An illustration showing the left and right buttocks with circular labeled injection sites marked 'OK' for acceptable subcutaneous injection locations. The diagram indicates proper injection sites for a subcutaneous injection product.*

FDA Label Image

Lanreotide Fig 11 (Lanreotide Fig 11)

An instructional illustration showing a hand wearing a glove wiping the buttock area, demonstrating preparation for a subcutaneous injection site. The image is related to the administration of an injection, consistent with LANREOTIDE ACETATE subcutaneous injection instructions.*

FDA Label Image

Lanreotide Fig 12 (Lanreotide Fig 12)

An instructional illustration showing a person holding a syringe and preparing or administering a subcutaneous injection using an injection device or prefilled syringe. The hands are positioned to handle the syringe safely, likely indicating steps in drug preparation or injection technique.*

FDA Label Image

Lanreotide Fig 13 (Lanreotide Fig 13)

An instructional illustration showing a person removing the needle cap from a prefilled syringe by pulling it straight off. The image emphasizes hand positioning and directional arrows for proper needle cap removal.*

FDA Label Image

Lanreotide Fig 14 (Lanreotide Fig 14)

An instructional line drawing showing a hand holding a syringe with a barrel and plunger, demonstrating the proper grip for injection administration.*

FDA Label Image

Lanreotide Fig 15 (Lanreotide Fig 15)

Instructional diagram showing proper hand positioning for subcutaneous injection of LANREOTIDE ACETATE. The top panel depicts a correct hand placement with an 'OK' symbol on the skin surface, while the bottom panel shows an incorrect hand placement crossed out with an X.*

FDA Label Image

Lanreotide Fig 16 (Lanreotide Fig 16)

An instructional diagram showing how to administer a LANREOTIDE ACETATE subcutaneous injection. The image illustrates correct hand positioning and injection angle of 90 degrees into the skin, highlighting proper injection technique with a check mark, and an incorrect technique with a cross mark.*

FDA Label Image

Lanreotide Fig 17 (Lanreotide Fig 17)

An instructional diagram showing a person administering a subcutaneous injection into the upper buttock/hip area using a syringe. The illustration displays the injection technique relevant for products like LANREOTIDE ACETATE injection.*

FDA Label Image

Lanreotide Fig 18 (Lanreotide Fig 18)

Instructional illustration demonstrating the correct technique for administering a LANREOTIDE ACETATE subcutaneous injection. It shows a hand holding a syringe with an arrow indicating the injection direction, accompanied by a clock graphic specifying a 20-second wait time.*

FDA Label Image

Lanreotide Fig 19 (Lanreotide Fig 19)

An instructional illustration showing a hand holding a syringe or injection device, with fingers positioned to push the plunger, and an arrow indicating the direction of injection or medication administration.*

FDA Label Image

Lanreotide Fig 20 (Lanreotide Fig 20)

An instructional illustration showing three steps for using a LANREOTIDE ACETATE subcutaneous injection syringe. The images depict hand positioning and directional arrows for removing and preparing the syringe prior to injection.*

FDA Label Image

Lanreotide Fig 21 (Lanreotide Fig 21)

An instructional illustration depicting a person cleaning the lower back or upper buttock area with a swab, likely demonstrating preparation for a subcutaneous injection site for lanreotide acetate injection.*

FDA Label Image

Lanreotide Fig 22 (Lanreotide Fig 22)

An instructional illustration showing a person disposing of a syringe with a needle cap into a sharps disposal container, demonstrating safe injection waste handling.*

FDA Label Image

Lanreotide Fig 23 (Lanreotide Fig 23)

An instructional illustration showing two hands holding a cluster of small spherical objects under a running water faucet, likely demonstrating a preparation step involving rinsing or wetting before administration or use.*

FDA Label Image

Lanreotide 60mg Carton Label (Lanreotide 60mg Carton Label)

Carton packaging label for Lanreotide Injection 60 mg/0.2 mL by Exelan Pharmaceuticals, Inc. The label shows the product name and strength prominently in multiple locations, with instructions to refrigerate at 2°C to 8°C and protect from light. The box indicates it contains one prefilled syringe and includes storage and usual dosage information. A barcode and manufacturer information are also visible.*

FDA Label Image

Lanreotide 60 mg Pouch Label (Lanreotide 60 mg Pouch Label)

Label for Lanreotide Injection 60 mg/0.2 mL subcutaneous injection by Exelan Pharmaceuticals, Inc. The label includes dosage strength, route, a note for healthcare professional administration, storage instructions to refrigerate at 2°C - 8°C, and a barcode. The label also displays the product name, prescription status, and manufacturer logo.*

FDA Label Image

Lanreotide Pouch Stick 60 mg (Lanreotide Pouch Stick 60 mg)

Packaging label artwork details for a 60 mg LANREOTIDE ACETATE injection pouch stick by Pharmathen. The label includes printing specifications, dimensions (77x38 mm), color information, material, and responsible graphic supervisor name. Contact and software used for design are also listed, along with logos and a disclaimer in Greek about content approval.*

FDA Label Image

Lanreotide Syringe 60mg (Lanreotide Syringe 60mg)

Packaging label for LANREOTIDE ACETATE injection showing artwork specifications. The label includes artwork name, dimensions (70x15 mm), printing color (black), graphic check by Grigoris Kalivas, and software used (Adobe Illustrator CS6). Contact name is Panagiotis Papanikolopoulos. The label is from etpa packaging with relevant quality certification marks.*

FDA Label Image

Lanreotide 90mg Carton Label (Lanreotide 90mg Carton Label)

Carton packaging label for Lanreotide Injection 90 mg/0.3 mL, a subcutaneous injection by Exelan Pharmaceuticals, Inc. The label includes storage instructions to refrigerate at 2°C to 8°C, dosage information, manufacturer details, a barcode, and contact information for questions. The active ingredient is lanreotide acetate.*

FDA Label Image

Lanreotide 90mg Pouch Label (Lanreotide 90mg Pouch Label)

Lanreotide Injection 90 mg/0.3 mL packaging label for deep subcutaneous injection. The label includes NDC 76282-719-67, storage instructions to refrigerate at 2°C to 8°C, a reminder to keep out of reach of children, and a note that the injection should be administered by a healthcare professional. The labeler is Exelan Pharmaceuticals, Inc.*

FDA Label Image

Lanreotide Pouch Stick 90 mg (Lanreotide Pouch Stick 90 mg)

Packaging label artwork specifications for LANREOTIDE ACETATE injection in a 90 mg strength pouch stick. The label shows dimensions of 77x38 mm with printing colors in black. It includes contact information for artwork supervision and special instructions noting a no varnish area, produced by Pharmathen with ETPA packaging details.*

FDA Label Image

Lanreotide Syringe 90 mg (Lanreotide Syringe 90 mg)

Packaging label artwork for LANREOTIDE ACETATE injection, specifically the syringe form with 90 mg strength. The label includes artwork details such as dimensions 70x15mm, printing in black color, and the labeler information for Exelan Pharmaceuticals, Inc. The label also contains a customer service contact and special instructions including 'no varnish area' highlighted in red.*

FDA Label Image

Lanreotide 120 mg Carton Label (Lanreotide 120 mg Carton Label)

Packaging label for Lanreotide Injection 120 mg/0.5 mL, a subcutaneous injection by Exelan Pharmaceuticals, Inc. The label includes storage instructions to refrigerate at 2°C to 8°C and protect from light. It states that the box contains one prefilled syringe and includes manufacturer information for Pharmathen International, S.A., Greece, and Exelan Pharmaceuticals, Boca Raton, FL.*

FDA Label Image

Lanreotide 120 mg Pouch Label (Lanreotide 120 mg Pouch Label)

Label for Lanreotide Injection 120 mg/0.5 mL by Exelan Pharmaceuticals, Inc., for deep subcutaneous injection. The label highlights administration instructions, storage conditions at 2°C to 8°C, and cautions to keep out of reach of children. Includes NDC 76282-720-67 and a barcode on the right side.*

FDA Label Image

Lanreotide Pouch Stick 120 mg (Lanreotide Pouch Stick 120 mg)

Packaging label artwork specifications for LANREOTIDE ACETATE injection pouch stick with a strength of 120 mg/0.5 mL by Exelan Pharmaceuticals, Inc. The label measures 77x38 mm, printed in black on specified materials. Artwork created and checked by Pharmathen and associated graphic and customer service personnel are noted.*

FDA Label Image

Lanreotide Syringe 120 mg (Lanreotide Syringe 120 mg)

Packaging label for LANREOTIDE ACETATE injection artwork named 'SYRING LANREANDA 120mg LAIEXELA'. The label includes printing details such as dimensions (70x15mm), code number (2834913), date (20/10/2023), color (black), and special instruction 'no varnish area'. Listed is the software used (Adobe Illustrator CS6) and contact for artwork supervision (Panagiotis Papanikopolous). The label is from ETPA Packaging with quality and environmental certification logos.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.